FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076380054> ?p ?o ?g. }

• W2076380054 endingPage "3201" @default.
• W2076380054 startingPage "3186" @default.
• W2076380054 abstract "The structure-activity relationships of 6-phenyl-1,4-dihydropyridine derivatives as selective antagonists at human A3 adenosine receptors have been explored (Jiang et al. J. Med. Chem. 1997, 39, 4667-4675). In the present study, related pyridine derivatives have been synthesized and tested for affinity at adenosine receptors in radioligand binding assays. Ki values in the nanomolar range were observed for certain 3,5-diacyl-2,4-dialkyl-6-phenylpyridine derivatives in displacement of [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)-5'-N-methylcarbamoyladenosine) at recombinant human A3 adenosine receptors. Selectivity for A3 adenosine receptors was determined vs radioligand binding at rat brain A1 and A2A receptors. Structure-activity relationships at various positions of the pyridine ring (the 3- and 5-acyl substituents and the 2- and 4-alkyl substituents) were probed. A 4-phenylethynyl group did not enhance A3 selectivity of pyridine derivatives, as it did for the 4-substituted dihydropyridines. At the 2- and 4-positions ethyl was favored over methyl. Also, unlike the dihydropyridines, a thioester group at the 3-position was favored over an ester for affinity at A3 adenosine receptors, and a 5-position benzyl ester decreased affinity. Small cycloalkyl groups at the 6-position of 4-phenylethynyl-1,4-dihydropyridines were favorable for high affinity at human A3 adenosine receptors, while in the pyridine series a 6-cyclopentyl group decreased affinity. 5-Ethyl 2, 4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate , 38, was highly potent at human A3 receptors, with a Ki value of 20 nM. A 4-propyl derivative, 39b, was selective and highly potent at both human and rat A3 receptors, with Ki values of 18.9 and 113 nM, respectively. A 6-(3-chlorophenyl) derivative, 44, displayed a Ki value of 7.94 nM at human A3 receptors and selectivity of 5200-fold. Molecular modeling, based on the steric and electrostatic alignment (SEAL) method, defined common pharmacophore elements for pyridine and dihydropyridine structures, e.g., the two ester groups and the 6-phenyl group. Moreover, a relationship between affinity and hydrophobicity was found for the pyridines." @default.
• W2076380054 created "2016-06-24" @default.
• W2076380054 creator A5008583952 @default.
• W2076380054 creator A5051346410 @default.
• W2076380054 creator A5081249838 @default.
• W2076380054 creator A5086091458 @default.
• W2076380054 creator A5091587615 @default.
• W2076380054 date "1998-07-21" @default.
• W2076380054 modified "2023-09-26" @default.
• W2076380054 title "Structure−Activity Relationships and Molecular Modeling of 3,5-Diacyl-2,4-dialkylpyridine Derivatives as Selective A₃ Adenosine Receptor Antagonists" @default.
• W2076380054 cites W1545295983 @default.
• W2076380054 cites W1851816342 @default.
• W2076380054 cites W1914750790 @default.
• W2076380054 cites W1976365557 @default.
• W2076380054 cites W2004999698 @default.
• W2076380054 cites W2013795726 @default.
• W2076380054 cites W2038168267 @default.
• W2076380054 cites W2044257233 @default.
• W2076380054 cites W2054906104 @default.
• W2076380054 cites W2059153581 @default.
• W2076380054 cites W2066804401 @default.
• W2076380054 cites W2067182243 @default.
• W2076380054 cites W2067737441 @default.
• W2076380054 cites W2074631079 @default.
• W2076380054 cites W2084335049 @default.
• W2076380054 cites W2084839593 @default.
• W2076380054 cites W2086992009 @default.
• W2076380054 cites W2092036055 @default.
• W2076380054 cites W2127823171 @default.
• W2076380054 cites W2133679578 @default.
• W2076380054 cites W2137056475 @default.
• W2076380054 cites W2148759019 @default.
• W2076380054 cites W2169920833 @default.
• W2076380054 cites W2270408884 @default.
• W2076380054 cites W2331486720 @default.
• W2076380054 cites W2409916978 @default.
• W2076380054 cites W2487216879 @default.
• W2076380054 cites W4236375831 @default.
• W2076380054 doi "https://doi.org/10.1021/jm980093j" @default.
• W2076380054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3474377" @default.
• W2076380054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9703464" @default.
• W2076380054 hasPublicationYear "1998" @default.
• W2076380054 type Work @default.
• W2076380054 sameAs 2076380054 @default.
• W2076380054 citedByCount "108" @default.
• W2076380054 countsByYear W20763800542012 @default.
• W2076380054 countsByYear W20763800542013 @default.
• W2076380054 countsByYear W20763800542014 @default.
• W2076380054 countsByYear W20763800542015 @default.
• W2076380054 countsByYear W20763800542016 @default.
• W2076380054 countsByYear W20763800542017 @default.
• W2076380054 countsByYear W20763800542018 @default.
• W2076380054 countsByYear W20763800542019 @default.
• W2076380054 countsByYear W20763800542020 @default.
• W2076380054 countsByYear W20763800542021 @default.
• W2076380054 countsByYear W20763800542022 @default.
• W2076380054 countsByYear W20763800542023 @default.
• W2076380054 crossrefType "journal-article" @default.
• W2076380054 hasAuthorship W2076380054A5008583952 @default.
• W2076380054 hasAuthorship W2076380054A5051346410 @default.
• W2076380054 hasAuthorship W2076380054A5081249838 @default.
• W2076380054 hasAuthorship W2076380054A5086091458 @default.
• W2076380054 hasAuthorship W2076380054A5091587615 @default.
• W2076380054 hasBestOaLocation W20763800542 @default.
• W2076380054 hasConcept C116569031 @default.
• W2076380054 hasConcept C155647269 @default.
• W2076380054 hasConcept C170493617 @default.
• W2076380054 hasConcept C185592680 @default.
• W2076380054 hasConcept C2776991684 @default.
• W2076380054 hasConcept C2778938600 @default.
• W2076380054 hasConcept C2779485729 @default.
• W2076380054 hasConcept C55493867 @default.
• W2076380054 hasConcept C67847695 @default.
• W2076380054 hasConcept C67907053 @default.
• W2076380054 hasConcept C71240020 @default.
• W2076380054 hasConceptScore W2076380054C116569031 @default.
• W2076380054 hasConceptScore W2076380054C155647269 @default.
• W2076380054 hasConceptScore W2076380054C170493617 @default.
• W2076380054 hasConceptScore W2076380054C185592680 @default.
• W2076380054 hasConceptScore W2076380054C2776991684 @default.
• W2076380054 hasConceptScore W2076380054C2778938600 @default.
• W2076380054 hasConceptScore W2076380054C2779485729 @default.
• W2076380054 hasConceptScore W2076380054C55493867 @default.
• W2076380054 hasConceptScore W2076380054C67847695 @default.
• W2076380054 hasConceptScore W2076380054C67907053 @default.
• W2076380054 hasConceptScore W2076380054C71240020 @default.
• W2076380054 hasIssue "17" @default.
• W2076380054 hasLocation W20763800541 @default.
• W2076380054 hasLocation W20763800542 @default.
• W2076380054 hasLocation W20763800543 @default.
• W2076380054 hasLocation W20763800544 @default.
• W2076380054 hasOpenAccess W2076380054 @default.
• W2076380054 hasPrimaryLocation W20763800541 @default.
• W2076380054 hasRelatedWork W1854071822 @default.
• W2076380054 hasRelatedWork W1866763656 @default.
• W2076380054 hasRelatedWork W1984747442 @default.
• W2076380054 hasRelatedWork W1986087013 @default.
• W2076380054 hasRelatedWork W2002114193 @default.

• next